Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Vornorexant (TS-142) in Healthy Volunteers
NCT04464239Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (3 cohorts), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence and severity of Adverse Events, TS-142 Plasma Pharmacokinetic Profile - Cmax and 6 more. Started Sep 2020; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04464239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464239.